Subscribe to our RSS feeds RSS | Login | Register  
 

Industry News

Watchdogs want FDA number in ads

Matthew Arnold May 01, 2008

Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.
 

LLNS rebrands as LyonHeart

Stephen McGuire June 05, 2007

Lyons Lavey Nickel Swift is rebranding as “LyonHeart” under its proprietary creative-strategic process dubbed “Disruption.”
 

AMA hooks up online with Sermo

Matthew Arnold June 05, 2007

The American Medical Association announced it is partnering with Sermo, the online community for physicians.
 

GlaxoSmithKline faces more Avandia fallout

Matthew Arnold, Marc Iskowitz June 05, 2007

GlaxoSmithKline is in Congressional crosshairs over its marketing of Avandia, and investors arent happy either.
 

Nexavar also seen as liver cancer breakthrough

Stephen McGuire June 04, 2007

Onyx and Bayers kidney cancer drug Nexavar (sorafenib) was also found to extend the lives of liver cancer patients in a clinical trial by almost three months, or 44%, doctors said.
 

InVentiv buys brand ID shop Addison Whitney

Matthew Arnold May 31, 2007

InVentiv Health has acquired brand identity shop Addison Whitney.
 

Panel to review Sanofi-Aventis’ Ketek

November 15, 2006

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
 

Panel to review Sanofi-Aventis’ Ketek

November 15, 2006

The FDA will convene a joint panel of outside experts to examine the risks and benefits of Sanofi-Aventis’ antibiotic Ketek (telithromycin).
 

AHA forbids Pfizer from presenting torcetrapib results

November 14, 2006

Pfizer won’t be allowed to present new data on its closely watched developmental drug torcetrapib at the annual American Heart Association (AHA) meeting this week.
 

Novartis asks FDA for Galvus review extension

November 14, 2006

Novartis has asked the FDA to extend the review period for its highly anticipated developmental diabetes drug Galvus by three months to allow the agency to examine new clinical trials data.
 
 Subscribe to the RSS for this page  [view all our RSS feeds here]
 
Popular Tags
Advertising Agency Approval Awards Biotech Brand Clinical trial Continuing medical education (CME) Digital Direct marketing Direct to consumer (DTC) Education & Awareness FDA Government Launch Legal Magazine Marketing & Communications Marketing Research Media New hire Pharmaceutical Professional Promotion Sales force